within Pharmacolibrary.Drugs.ATC.S;

model S01XA13
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.009166666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.016,
    k12             = 420,
    k21             = 420
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA13</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent to treat acute ischemic stroke, acute myocardial infarction, and pulmonary embolism. It acts by catalyzing the conversion of plasminogen to plasmin, leading to the dissolution of blood clots. Alteplase is approved and in current clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed predominantly in healthy adult volunteers and patients with myocardial infarction after intravenous administration.</p><h4>References</h4><ol><li><p>Wang, L, et al., &amp; Xiong, Y (2024). Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> 13(9) e031692–None. DOI:<a href=&quot;https://doi.org/10.1161/JAHA.123.031692&quot;>10.1161/JAHA.123.031692</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38686848/&quot;>https://pubmed.ncbi.nlm.nih.gov/38686848</a></p></li><li><p>Glund, S, et al., &amp; Wolff, M (2023). Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study. <i>Clinical pharmacokinetics</i> 62(7) 1023–1030. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01253-3&quot;>10.1007/s40262-023-01253-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37248330/&quot;>https://pubmed.ncbi.nlm.nih.gov/37248330</a></p></li><li><p>Larrue, V (2005). Intravenous alteplase for acute ischaemic stroke. <i>Expert opinion on pharmacotherapy</i> 6(15) 2699–2709. DOI:<a href=&quot;https://doi.org/10.1517/14656566.6.15.2699&quot;>10.1517/14656566.6.15.2699</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16316308/&quot;>https://pubmed.ncbi.nlm.nih.gov/16316308</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA13;
